Neurocrine Biosciences Inc
NASDAQ:NBIX
Neurocrine Biosciences Inc
NASDAQ:NBIX
Price:
143.03 USD
3.99%
Market Closed
Updated:
May 2, 2024
Neurocrine Biosciences Inc
Net Income (Common)
|
Neurocrine Biosciences Inc
Net Income (Common) Peer Comparison
Comparables:
ABBV
GILD
AMGN
VRTX
REGN
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Neurocrine Biosciences Inc
NASDAQ:NBIX
|
Net Income (Common)
$249.7m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.8B
|
CAGR 3-Years
2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
2%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$484m
|
CAGR 3-Years
17%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-20%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$6.7B
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
$3.6B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4B
|
CAGR 3-Years
4%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is Neurocrine Biosciences Inc's Net Income (Common)?
Net Income (Common)
249.7m
USD
249.7m
USD
Based on the financial report for Dec 31, 2023, Neurocrine Biosciences Inc's Net Income (Common) amounts to 249.7m USD.
What is Neurocrine Biosciences Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
64%
64%
Over the last year, the Net Income (Common) growth was 62%. The average annual Net Income (Common) growth rates for Neurocrine Biosciences Inc have been -15% over the past three years , 64% over the past five years .
You don't have any saved screeners yet
